1. Home
  2. FGBI vs BMEA Comparison

FGBI vs BMEA Comparison

Compare FGBI & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FGBI
  • BMEA
  • Stock Information
  • Founded
  • FGBI 1934
  • BMEA 2017
  • Country
  • FGBI United States
  • BMEA United States
  • Employees
  • FGBI N/A
  • BMEA N/A
  • Industry
  • FGBI Savings Institutions
  • BMEA Biotechnology: Pharmaceutical Preparations
  • Sector
  • FGBI Finance
  • BMEA Health Care
  • Exchange
  • FGBI Nasdaq
  • BMEA Nasdaq
  • Market Cap
  • FGBI 121.5M
  • BMEA 103.5M
  • IPO Year
  • FGBI N/A
  • BMEA 2021
  • Fundamental
  • Price
  • FGBI $7.84
  • BMEA $1.83
  • Analyst Decision
  • FGBI
  • BMEA Strong Buy
  • Analyst Count
  • FGBI 0
  • BMEA 10
  • Target Price
  • FGBI N/A
  • BMEA $17.70
  • AVG Volume (30 Days)
  • FGBI 3.6K
  • BMEA 674.3K
  • Earning Date
  • FGBI 08-18-2025
  • BMEA 08-05-2025
  • Dividend Yield
  • FGBI 0.50%
  • BMEA N/A
  • EPS Growth
  • FGBI N/A
  • BMEA N/A
  • EPS
  • FGBI N/A
  • BMEA N/A
  • Revenue
  • FGBI $59,070,000.00
  • BMEA N/A
  • Revenue This Year
  • FGBI N/A
  • BMEA N/A
  • Revenue Next Year
  • FGBI $3.38
  • BMEA N/A
  • P/E Ratio
  • FGBI N/A
  • BMEA N/A
  • Revenue Growth
  • FGBI N/A
  • BMEA N/A
  • 52 Week Low
  • FGBI $6.56
  • BMEA $1.29
  • 52 Week High
  • FGBI $15.25
  • BMEA $13.07
  • Technical
  • Relative Strength Index (RSI)
  • FGBI 40.14
  • BMEA 56.62
  • Support Level
  • FGBI $7.70
  • BMEA $1.51
  • Resistance Level
  • FGBI $8.08
  • BMEA $1.86
  • Average True Range (ATR)
  • FGBI 0.19
  • BMEA 0.10
  • MACD
  • FGBI -0.03
  • BMEA 0.03
  • Stochastic Oscillator
  • FGBI 19.67
  • BMEA 91.67

About FGBI First Guaranty Bancshares Inc.

First Guaranty Bancshares Inc provides personalized commercial banking services to its customers in Louisiana, through several banking facilities. The principal business activity of the company includes attracting deposits and investing it together with funds generated from operations and borrowings insecurities and in lending activities to serve the credit needs of its customer base. The company offers commercial real estate loans, commercial and industrial loans, construction and land development loans, agricultural and farmland loans, and to a lesser extent, consumer and multifamily loans.

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.

Share on Social Networks: